NCT lookup

Inclusion criteria :

* Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations.
* No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease).
* Expression of CEACAM5 as demonstrated prospectively by a centrally assessed Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 1% of the tumor cell population in archival tumor sample (or if not available fresh biopsy sample).
* Measurable disease based on RECIST 1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Life expectancy of at least 3 months

Exclusion criteria:

* Medical condition requiring concomitant administration of a medication with a strong CYP3A inhibitor.
* Uncontrolled brain metastases and history of leptomeningeal disease.
* Significant concomitant illness, including any severe medical condition that, in the opinion of the investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
* History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
* History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C infection.
* History of active autoimmune disease that has required systemic treatment in the past 2 years.
* History of allogeneic tissue/solid organ transplantation.
* Active infection requiring IV systemic therapy within 2 weeks prior to randomization or active tuberculosis.
* Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
* Non-resolution of any prior treatment-related toxicity to \< Grade 2 according to NCI CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy.
* Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact lenses is not permitted.
* Symptomatic herpes zoster within 3 months prior to screening.
* Significant allergies to humanized monoclonal antibodies.
* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A \[IgA\] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
* Concurrent treatment with any other anticancer therapy.
* Have received prior chemotherapy treatment for advanced/metastatic NSCLC.
* The patient is a candidate for a curative treatment with either surgical resection and/or chemoradiation
* Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for any investigational treatment).
* Any prior therapy targeting CEACAM5.
* Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.
* Any prior maytansinoid treatment (DM1 or DM4 ADC).
* Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication. Daily steroid replacement therapy or any corticosteroid premedication if applicable are allowed.
* Any radiation therapy to lung \>30 Gy within 6 months of first study intervention administration.
* Has received or will receive a live vaccine within 30 days prior to the first study intervention administration.
* Any major surgery within the preceding 3 weeks of the first study intervention administration.

Prior/concurrent clinical study experience

* Current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
* Poor organ function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Westwood, Kansas, United States
• Natal, Rio Grande do Norte, Brazil
• Temuco, La Araucanía, Chile
• Viña del Mar, Valparaiso, Chile
• Santiago, Chile
• Santiago, Chile
• Olomouc, Czechia
• Ostrava - Vitkovice, Czechia
• Avignon, France
• Brest, France
• Pessac, France
• Poitiers, France
• Budapest, Hungary
• Farkasgyepü, Hungary
• Ramat Gan, Israel
• Tel Aviv, Israel
• A Coruña, A Coruña [La Coruña], Spain
• Badalona, Catalunya [Cataluña], Spain
• Oviedo, Principality of Asturias, Spain
• Las Palmas, Spain
• Madrid, Spain
• Madrid, Spain